Pharmaceutical compositions for use in the treatment of brain injuries or demyelinating disorders

The invention is in the field of neuroregenerative medicine. Controlling the fate of neural stem cells represents a key therapeutic strategy in neuroregenerative medicine. The inventors used in silico genomic approaches, searchable platform-independent expression database/connectivity map (SPIED/CMAP) strategy, to identify small molecules that are predicted to regulate transcriptional changes associated with neurogenesis in the subventricular zone (SVZ) neurogenic niche. The approach was validated by demonstrating that two of the identified small molecules, inhibiting PI3K/Akt and GSK3beta respectively, were able to differentially direct the fate of NSCs in vivo, to promote oligodendrogenesis and neurogenesis, in the postnatal and adult SVZ. The present invention thus relates to methods and pharmaceutical composition for use in the treatment of brain injuries or demyelinating disorders, and in particular to PI3K or GSK3beta inhibitors for use in treating brain injuries, such as perinatal hypoxia/ischemia, or demyelinating disorders such as periventricular leukomalacias or multiple sclerosis.

Keywords: neuroregenerative medicine, brain injuries, demyelinating disorders
Patent Application number: EP17305356.2
Inventors:
Kasum AZIMOlivier RAINETEAUArthur Morgan BUTT
Publications:
Pharmacogenomic identification of small molecules for lineage specific manipulation of subventricular zone germinal activity. Azim K. et al. PLoS Biol. 2017 Mar 28;15(3)

You might also be interested in